文献速递妇科肿瘤

奥拉帕利联合α特异性PI3K抑制剂阿培利司治疗上皮性卵巢癌患者的1b期剂量递增与剂量扩展试验

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
PubMed 文献 · Lancet Oncol · 2019-03-14

这项多中心、开放标签、1b期试验采用3+3剂量递增设计,纳入34例患者(剂量递增队列28例,剂量扩展队列6例),评估奥拉帕利联合阿培利司的安全性并确定II期推荐剂量。最大耐受剂量和II期推荐剂量为阿培利司200mg每日一次联合奥拉帕利200mg每日两次(剂量水平3)。28例上皮性卵巢癌患者中,10例(36%)达到部分缓解,14例(50%)疾病稳定。

要点

  • 最大耐受剂量和II期推荐剂量为阿培利司200mg每日一次联合奥拉帕利200mg每日两次。
  • 最常见治疗相关3-4级不良事件为高血糖(5例[16%])、恶心(3例[9%])和丙氨酸氨基转移酶升高(3例[9%])。
  • 28例上皮性卵巢癌患者中,10例(36%)部分缓解,14例(50%)疾病稳定。

核心结论

  • 阿培利司联合奥拉帕利可行,未出现非预期毒性效应。
  • 观察到的活性为奥拉帕利与阿培利司协同作用提供初步临床证据,尤其在上皮性卵巢癌中,值得进一步研究。

研究设计与样本

  • 多中心、开放标签、1b期试验,采用3+3剂量递增设计,并设剂量扩展队列。
  • 2014年10月3日至2016年12月21日入组34例患者,剂量递增队列28例,剂量扩展队列6例;剂量递增队列中2例在计划研究开始当日不符合入组条件。
  • 分析纳入所有接受至少一剂研究药物的患者。

主要发现

  • 最大耐受剂量和II期推荐剂量为阿培利司200mg每日一次联合奥拉帕利200mg每日两次(剂量水平3)。
  • 所有剂量水平中,最常见治疗相关3-4级不良事件为高血糖(5例[16%])、恶心(3例[9%])和丙氨酸氨基转移酶升高(3例[9%])。
  • 未发生治疗相关死亡。
  • 剂量限制性毒性包括高血糖和发热伴中性粒细胞计数降低。
  • 28例上皮性卵巢癌患者中,根据实体瘤疗效评价标准1.1,10例(36%)达到部分缓解,14例(50%)疾病稳定。

关键数值与推荐

  • 计划四个剂量水平:剂量水平0为阿培利司250mg每日一次联合奥拉帕利100mg每日两次;剂量水平1为阿培利司250mg每日一次联合奥拉帕利200mg每日两次;剂量水平2为阿培利司300mg每日一次联合奥拉帕利200mg每日两次;剂量水平3为阿培利司200mg每日一次联合奥拉帕利200mg每日两次。
  • 最大耐受剂量和II期推荐剂量确定为阿培利司200mg每日一次联合奥拉帕利200mg每日两次(剂量水平3)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文结论指出观察到的活性为初步临床证据,值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Based on preclinical work, we found that combination of poly (ADP-ribose) polymerase (PARP) inhibitors with drugs that inhibit the homologous recombination repair (HRR) pathway (such as PI3K inhibitors) might sensitise HRR-proficient epithelial ovarian cancers to PARP inhibitors. We aimed to assess the safety and identify the recommended phase 2 dose of the PARP inhibitor olaparib in combination with the PI3K inhibitor alpelisib in patients with epithelial ovarian cancer and in patients with breast cancer. METHODS: In this multicentre, open-label, phase 1b trial following a 3 + 3 dose-escalation design, we recruited patients aged 18 years or older with the following key eligibility criteria: confirmed diagnosis of either recurrent ovarian, fallopian tube, or primary peritoneal cancer of high-grade serous histology; confirmed diagnosis of either recurrent ovarian, fallopian tube, or primary peritoneal cancer of any histology with known germline BRCA mutations; confirmed diagnosis of recurrent breast cancer of triple-negative histology; or confirmed diagnosis of recurrent breast cancer of any histology with known germline BRCA mutations. Additional patients with epithelial ovarian cancer were enrolled in a dose-expansion cohort. Four dose levels were planned: the starting dose level of alpelisib 250 mg once a day plus olaparib 100 mg twice a day (dose level 0); alpelisib 250 mg once a day plus olaparib 200 mg twice a day (dose level 1); alpelisib 300 mg once a day plus olaparib 200 mg twice a day (dose level 2); and alpelisib 200 mg once a day plus olaparib 200 mg twice a day (dose level 3). Both drugs were administered orally, in tablet formulation. The primary objective was to identify the maximum tolerated dose and the recommended phase 2 dose of the combination of alpelisib and olaparib for patients with epithelial ovarian cancer and patients with breast cancer. Analyses included all patients who received at least one dose of the study drugs. The trial is active, but closed to enrolment; follow-up for patients who completed treatment is ongoing. This trial is registered with ClinicalTrials.gov, number NCT01623349. FINDINGS: Between Oct 3, 2014, and Dec 21, 2016, we enrolled 34 patients (28 in the dose-escalation cohort and six in the dose-expansion cohort); two in the dose-escalation cohort were ineligible at the day of scheduled study initiation. Maximum tolerated dose and recommended phase 2 dose were identified as alpelisib 200 mg once a day plus olaparib 200 mg twice a day (dose level 3). Considering all dose levels, the most common treatment-related grade 3-4 adverse events were hyperglycaemia (five [16%] of 32 patients), nausea (three [9%]), and increased alanine aminotransferase concentrations (three [9%]). No treatment-related deaths occurred. Dose-limiting toxic effects included hyperglycaemia and fever with decreased neutrophil count. Of the 28 patients with epithelial ovarian cancer, ten (36%) achieved a partial response and 14 (50%) had stable disease according to Response Evaluation Criteria in Solid Tumors 1.1. INTERPRETATION: Combining alpelisib and olaparib is feasible with no unexpected toxic effects. The observed activity provides preliminary clinical evidence of synergism between olaparib and alpelisib, particularly in epithelial ovarian cancer, and warrants further investigation. FUNDING: Ovarian Cancer Dream Team (Stand Up To Cancer, Ovarian Cancer Research Alliance, National Ovarian Cancer Coalition), Breast Cancer Research Foundation, Novartis.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Konstantinopoulos PA, Barry WT, Birrer M, et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019. PMID: 30880072. doi:10.1016/S1470-2045(18)30905-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。